GlobeNewswire Inc.··NaKymera Therapeutics Lands $45M Milestone as FDA Fast-Tracks Asthma Drug
Kymera Therapeutics receives $45M from Gilead option exercise and FDA Fast Track designation for asthma drug KT-621, with Phase 2b data expected late 2027.
GILDKYMRasthmaGilead Sciences